SCHEMBL6494733

SCHEMBL6494733

CC(C)(C)OC(=O)NS(=O)(=O)Cc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.67
CA12 O43570 3/20 0.67
CA7 P43166 2/20 0.67
CA14 Q9ULX7 2/20 0.67
STS P08842 1/20 0.60
CA2 P00918 2/20 0.51
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51
MMP8 P22894 1/20 0.51
MMP13 P45452 1/20 0.51
ATM Q13315 2/20 0.50
MAPT P10636 1/20 0.50
AKT1 P31749 2/20 0.49
HPGD P15428 2/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
PKM P14618 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926757 0.86 CA12 (0.51) CA1CA12CA7CA14STS
SCHEMBL30193288 0.83 CTSS (0.64) ATMAKT1HPGDMEN1ALDH1A1
SCHEMBL20379753 0.82 HPGD (0.59) CA1CA12CA7CA14STS
SCHEMBL6337412 0.80 CA12 (1.00) CA1CA12CA7CA14CA2
SCHEMBL12862920 0.80 CA1 (0.55) CA1CA12CA7CA14STS
SCHEMBL7464176 0.80 PPARA (0.56) CA1CA12CA7CA14ATM
SCHEMBL7464166 0.80 PPARA (0.56) CA1CA12CA7CA14ATM
SCHEMBL15779079 0.79 GAA (0.54) CA1CA12CA2MMP1MMP2
SCHEMBL7709249 0.79 CA2 (0.56) CA2MAPTMEN1ALDH1A1LMNA
SCHEMBL8244755 0.78 CA12 (0.75) CA1CA12CA7CA14CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108069976-A A kind of nitrogenous macrocyclic compounds, its preparation method, pharmaceutical composition and application 山东罗欣药业集团股份有限公司 2018-05-25 CN disclosed
US-6855725-B2 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY (US) 2005-02-15 US disclosed
US-20040063749-A1 Excitatory amino acid receptor antagonists BLEISCH THOMAS JOHN (US) 2004-04-01 US disclosed
EP-1351952-A2 PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-10-15 EP disclosed
WO-2002053556-A2 PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063749-A1 Excitatory amino acid receptor antagonists SLC1A2, SLC1A1, SLC1A3 CA1 946/4885CA12 2725/4885CA7 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.